Equillium's stock tumbles after decision to not initiate late-stage trial of COVID-19 treatmentMarket Watch • 11/25/20
Equillium Reports Third Quarter 2020 Financial Results and Business HighlightsGlobeNewsWire • 11/10/20
Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host DiseaseGlobeNewsWire • 11/06/20
Equillium to Present Data at the 2020 American College of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney and Skin Pathology in Preclinical Models of Systemic Lupus ErythematosusGlobeNewsWire • 11/04/20
Equillium Presented New Data and Insights on the CD6-ALCAM Pathway in Uncontrolled Asthma at the European Respiratory Society International Congress 2020GlobeNewsWire • 09/17/20
Equillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab into a Potential Registration Study as a Treatment for Hospitalized COVID-19 PatientsGlobeNewsWire • 09/15/20
Equillium to Present at H.C. Wainwright 22nd Annual Global Investment ConferenceGlobeNewsWire • 09/03/20
Equillium Reports Second Quarter 2020 Financial Results and Recent HighlightsGlobeNewsWire • 08/12/20
Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD StudyGlobeNewsWire • 08/10/20
Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19GlobeNewsWire • 07/13/20
Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park CapitalGlobeNewsWire • 03/30/20